Why the study?
Does an early invasive strategy reduce major cardiac events in patients with unstable angina and NSTEMI treated with tirofiban?
Does an early invasive strategy reduce major cardiac events in patients with unstable angina and NSTEMI treated with tirofiban?
An early invasive strategy significantly reduces major cardiac events in patients with unstable angina and NSTEMI receiving glycoprotein IIb/IIIa inhibition.
Supports early invasive strategy in UA/NSTEMI on tirofiban; confirms benefit of invasive management in high-risk ACS.
In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events. These data support a policy involving broader use of the early inhibition of glycoprotein IIb/IIIa in combination with an early invasive strategy in such patients.
No takes yet. Share an insight, caveat, or question.
Cannon et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: